The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 328:1372-1376 May 13, 1993 Number 19
NextNext

Blood Transfusions and Prognosis in Colorectal Cancer
Olivier Busch, Wim Hop, Marlene Hoynck van Papendrecht, Richard L. Marquet, and Johannes Jeekel

 Sign up for free e-toc
 

This Article
-Full Text

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported.

Methods We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group were required to donate two units of blood before surgery.

Results A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those in the autologous-transfusion group had no recurrence of colorectal cancer at four years (P = 0.93). We also found that the risk of recurrence was significantly increased in patients who received blood transfusions, either allogeneic or autologous, as compared with patients who did not require transfusions; the relative rates of recurrence were 2.1 (P = 0.01) and 1.8 (P = 0.04), respectively; these rates did not differ significantly from each other.

Conclusions The use of autologous blood as compared with allogeneic blood for transfusion does not improve the prognosis in patients with colorectal cancer. Regardless of their type, transfusions are associated with poor prognosis, probably because of the circumstances that necessitate them.


Source Information

From the Department of Surgery, University Hospital Rotterdam-Dijkzigt and Erasmus University (O.R.C.B., M.A.W.H.P., R.L.M., J.J.), and the Department of Epidemiology and Biostatistics, Erasmus University (W.C.J.H.), Rotterdam, the Netherlands.

Address reprint requests to Dr. Jeekel at the Department of Surgery, University Hospital Rotterdam-Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.

Full Text of this Article


Related Letters:

Blood Transfusions and Prognosis in Colorectal Cancer
Ross W. B., Blumberg N., Heal J. M., Busch O. R.C., Marquet R. L., Hop W. C.J., Jeekel J.
Extract | Full Text  
N Engl J Med 1993; 329:1354-1356, Oct 28, 1993. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.